The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

January 10, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

Coenzyme Q10

"100 mg once daily starting after the first chemotherapy cycle. Patients will receive 12 cycles of the modified FOLFOX-6 regimen with Coenzyme Q10 (100 mg once daily in the morning), starting after the first chemotherapy cycle and continuing until the end of the 12th cycle. Based on McRae (2023), 200 mg/day for 12 weeks reduced TNF-α and IL-6; thus, 100 mg/day for 6 months was selected (one cycle every 2 weeks = 24 weeks).~Supportive care: Includes a 5-HT3 antagonist for nausea prevention and pantoprazole to prevent gastric irritation.~Intervention Details:~Oxaliplatin: Part of the FOLFOX-6 regimen. 5-Fluorouracil (5-FU): Part of the FOLFOX-6 regimen. Leucovorin: Part of the FOLFOX-6 regimen. 5-HT3 Antagonist: Used for nausea prevention. Pantoprazole: Used to prevent gastric irritation."

DRUG

Oxaliplatin

Part of the modified FOLFOX-6 chemotherapy regimen

DRUG

5-Fluorouracil (5-FU)

Part of the modified FOLFOX-6 chemotherapy regimen.

DRUG

5-HT3 Antagonist

Used for nausea prevention during chemotherapy.

DRUG

Pantoprazole

Used to prevent gastric irritation during chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Ain-Shams University Hospital, Cairo

All Listed Sponsors
lead

toqa saad mohammed mohammed

OTHER